DEA Raises Psilocybin Quota 67%; Axsome Joins Five Psychedelic Therapy Race
The DEA raised its 2026 psilocybin production quota by 67% after a psilocybin compound posted two positive Phase 3 results in treatment-resistant depression. Axsome Therapeutics is one of five companies advancing psychedelic-based CNS therapies toward potential FDA filings.
1. DEA Raises 2026 Psilocybin Production Quota by 67%
The US Drug Enforcement Administration increased its 2026 psilocybin production quota by 67%, responding to positive Phase 3 readouts in treatment-resistant depression and anticipating higher demand for clinical research and manufacturing of psychedelic-based therapies.
2. Axsome’s Position in the CNS Psychedelic Market
Axsome Therapeutics is among five biotechs targeting regulatory approval of psilocybin and related compounds for CNS disorders, leveraging expanded federal supply and momentum from successful Phase 3 trials to advance its own pipeline toward FDA review.